Testing BAT3306 vs Keytruda for lung cancer after surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called BAT3306 against the approved drug Keytruda for people with non-small cell lung cancer after surgery. It aims to see if the new drug works as well or better in keeping cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have been diagnosed with non-small cell lung cancer after surgery, and a pathology report confirms this.
- Your tumor does not have an EGFR gene mutation.
- You have not had more than 4 rounds of chemotherapy after surgery, and no other cancer treatment before surgery.
- You have not received any immune checkpoint inhibitor drugs (like PD-1 or PD-L1 blockers) before.
- You do not have a serious active infection requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new medicine called QL2107 to the approved drug Keytruda in people with non-small cell lung cancer (NSCLC) that has been removed completely by surgery and treated with chemotherapy. The goal is to see if QL2107 works similarly to Keytruda in preventing the cancer from coming back.
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
This trial tests a new combination of drugs (Keytruda with or without chemotherapy) to see if it works better for advanced lung cancer. It's for people who haven't had immunotherapy or chemotherapy for their cancer that has spread.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
This trial tests if a new drug, MB12, works as well as Keytruda for people with advanced non-small cell lung cancer who haven't had treatment yet. It aims to offer a more affordable option.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.